ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Horsham: Johnson and Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to ...

Obinutuzumab (Gazyva) is the first drug to be approved for lupus nephritis since the approvals of belimumab (Benlysta) in 2020 and voclosporin (Lupkynis) in 2021.

For patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene ...

For patients with HRRm prostate cancer receiving Akeega and Zytiga with prednisone, quality of life remained at baseline.

Physicians and patient advocacy groups are rallying behind a renewed legislative effort in Congress to amend what they claim ...

“You can see that there was an initial reduction in the HR-QOL score in the niraparib arm, which may have been explained by the onset of the most frequently observed adverse events, which included ...

Ten months after having a baby, I received a devastating diagnosis – and it’s more common than you might think.

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

Roughly 6 months after starting tezepelumab for severe asthma, many patients reduced OCS dependence and meaningfully improved ...